This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Indian Pharmaceutical Market Outlook - Enhanced Purchasing Power, Rural Market Penetration And Expanded Access To Healthcare Attracting Big Pharma Investment

5.1.2 Biotech 38

5.1.3 Over-the-Counter Drugs 42

5.1.4 Prescription Drugs 42

5.1.5 Herbal Medicines 43

5.2 Market Segmentation 44

6 Indian Pharmaceutical Market Outlook – Market Analysis by Therapeutic Categories 46

6.1 Market Share of Leading Therapeutic Segment 46

6.2 Anti-Infectives 47

6.2.1 Market Size 47

6.2.2 Key Brands and Players 48

6.2.3 Recent Developments 48

6.2.4 Outlook 48

6.3 Cardiovascular System 49

6.3.1 Market Size 49

6.3.2 Recent Developments 50

6.3.3 Outlook 50

6.4 Gastrointestinal 51

6.4.1 Market Size 51

6.4.2 Recent Developments 52

6.4.3 Outlook 52

6.5 Diabetes 53

6.5.1 Market Size 53

6.5.2 Recent Developments 54

6.5.3 Outlook 54

6.6 Central Nervous System 55

6.6.1 Market Size 55

6.6.2 Recent Developments 56

6.6.3 Outlook 56

6.7 Respiratory 57

6.7.1 Market Size 57

6.7.2 Recent Developments 58

6.7.3 Outlook 58

6.8 Dermatology 59

6.8.1 Market Size 59

6.8.2 Recent Developments 60

6.8.3 Outlook 60

6.9 Oncology 61

6.9.1 Market Size 61

6.9.2 Recent Developments 62

6.9.3 Outlook 62

7 Indian Pharmaceutical Market Outlook – Key Trends 63

7.1 Rapid Consolidation and Rise of Multinational Corporations in the Indian Pharmaceutical Industry 63

7.1.1 M&A Deals 63

7.1.2 Licensing Deals 65

7.1.3 Partnership Deals 66

7.2 Patent Litigations Favoring Generics 67

7.2.1 Indian Patent Office Revokes Patent for Pfizer's Cancer Drug Sutent (sunitinib) 67

7.2.2 Indian Appeals Body Dismisses Bayer's Plea for Stay on Natco's Generic Nexavar (sorafenib) 67

7.2.3 Delhi High Court Rules in Favor of Cipla in Roche's Tarceva (erlotinib) Patent Lawsuit 67

7.2.4 Indian Supreme Court Asks Novartis to Scale Down Price of Cancer Drug Glivec (imatinib) 67

7.3 Increasing Importance of Rural Marketing in India 68

7.3.1 Case Study - Novartis Arogya Parivar Case Study 68

7.4 Product Localization and India-Specific Pricing 70

7.4.1 Case Study - GlaxoSmithKline, Localized Business Model 70

7.5 Sales Strategies 71

4 of 7

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs